11-Ketotestosterone and 11-Ketodihydrotestosterone in Castration Resistant Prostate Cancer: Potent Androgens Which Can No Longer Be Ignored
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Dihydrotestosterone (DHT) is regarded as the most potent natural androgen and is implicated in the development and progression of castration resistant prostate cancer (CRPC). Under castrate conditions, DHT is produced from the metabolism of the adrenal androgen precursors, DHEA and androstenedione. Recent studies have shown that the adrenal steroid 11β-hydroxyandrostenedione (11OHA4) serves as the precursor to the androgens 11-ketotestosterone (11KT) and 11-ketodihydrotestosterone (11KDHT). In this study we comprehensively assess the androgenic activity of 11KT and 11KDHT. This is the first study, to our knowledge, to show that 11KT and 11KDHT, like T and DHT, are potent and efficacious agonists of the human androgen receptor (AR) and induced both the expression of representative AR-regulated genes as well as cellular proliferation in the androgen dependent prostate cancer cell lines, LNCaP and VCaP. Proteomic analysis revealed that 11KDHT regulated the expression of more AR-regulated proteins than DHT in VCaP cells, while in vitro conversion assays showed that 11KT and 11KDHT are metabolized at a significantly lower rate in both LNCaP and VCaP cells when compared to T and DHT, respectively. Our findings show that 11KT and 11KDHT are bona fide androgens capable of inducing androgen-dependant gene expression and cell growth, and that these steroids have the potential to remain active longer than T and DHT due to the decreased rate at which they are metabolised. Collectively, our data demonstrates that 11KT and 11KDHT likely play a vital, but overlooked, role in the development and progression of CRPC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig 2 Binding of DHT, T, 11KDHT and 11KT to the human AR (A) and transactivation via an ARE (B and C). Binding affinities, agonist potencies and efficacies of DHT, 11KDHT, T and 11KT relative to the synthetic AR agonist mibolerone are summarised in (D). Whole cell binding assays (A) were conducted in COS-1 cells transiently transfected with pSVARo. Cells were incubated with 0.2 nM [3H]-Mib in the absence and presence of increasing concentrations of either unlabelled Mib, DHT, 11KDHT, T and 11KT for 16 hours. Results are plotted as % specific binding where the total specific binding of [3H]-Mib only is set to 100% and binding of unlabelled steroid is set as a % binding relative to that. Whole cell binding results are shown as means ± SEM of three independent experiments performed in triplicate. Transactivation assays (B and C) where performed in COS-1 cells transiently transfected with the pSVARo expression vector and the 4xSC ARE1.2-luc reporter. Agonist activity was measured by incubating cells in the presence of increasing concentrations of either Mib, DHT, T, 11KDHT or 11KT for 24 h. Induction is shown as % luciferase activity expressed in relative light units (rlu’s), with the maximal response of Mib (10−5 M) set to 100%. Luciferase assays are shown as means ± SEM of six independent experiments performed in quadruplicate.](https://figures.cochat.ai/paper-figures/99618cf761a440d99d5228b87dbb6f76/11-ketotestosterone-and-11-ketodihydrotestosterone-in-castration-resistant-figure-2.jpg)
![Fig 3 Induction of AR-regulated gene expression in LNCaP cells by DHT, 11KDHT and 11KT. Cells were incubated with CS-FCS-supplemented media for 24 hours prior to treatment with 1 or 10 nM steroid for an additional 24 hours prior to analysis by qPCR. Gene expression was calculated relative to the geometric mean of the reference genes ALAS and PBGD. Fold change over vehicle was calculated using the method described by Pfaffl et al [48]. Results are shown as means ± SEM of three independent experiments performed in triplicate. Data from individual experiments was all normalized using log transformation and mean-centering prior to analysis [49].](https://figures.cochat.ai/paper-figures/041a5f66ce2c452490998750f1db4851/11-ketotestosterone-and-11-ketodihydrotestosterone-in-castration-resistant-figure-3.jpg)
![Fig 4 Induction of AR-regulated gene expression in VCaP cells by DHT, 11KDHT, T and 11KT. Cells were incubated with CS-FCS supplemented media for 24 hours prior to treatment with 1 or 10 nM steroid for an additional 24 hours prior to analysis by qPCR. Gene expression was calculated relative to the geometric mean of the reference genes ALAS and PBGD and are expressed as the fold change over the vehicle control. Results are shown as means ± SEM of three independent experiments performed in triplicate. Data from individual experiments was all normalized using log transformation and mean-centering prior to analysis [49].](https://figures.cochat.ai/paper-figures/10542b2cdd9f4e1fbc1285f06a05c43b/11-ketotestosterone-and-11-ketodihydrotestosterone-in-castration-resistant-figure-4.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“11KA4 in turn serves as a substrate for AKR1C3 expressed in peripheral tissues such as adipose tissue, yielding 11KT, which binds and activates the human androgen receptor with an affinity and potency similar to that of testosterone [45,[70], [71], [72]].”
From Human steroid biosynthesis, metabolism and excretion are differentially reflected by serum and urine steroid metabolomes: a comprehensive review (2019) · cites this paper as [71]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“11KT is a potent androgen, with bioactivity similar to that of T (25–27).”
From 24-Hour Profiles of 11-Oxygenated C19 Steroids and Δ5-Steroid Sulfates during Oral and Continuous Subcutaneous Glucocorticoids in 21-Hydroxylase Deficiency (2021) · cites this paper as [27]
The cited source says what the claim attributes to it.
In the citing paper
“11KT can activate androgen-dependent processes with a similar potency to T12”
From Steroid hormone profiling reveals altered adrenal androgen production in endometriosis (2026) · cites this paper as [12]
In the citing paper
“including, 11ketotestosterone and 11-keto-DHT, androgens that bind and activate the androgen receptor.128,129”
From Congenital adrenal hyperplasia (2017) · cites this paper as [128]
In the citing paper
“While 11OHT and 11OHDHT represent partial AR agonists, 11KT and 11KDHT are full agonists with the same AR activating potential as T and DHT, respectively (Pretorius et al., 2016, Storbeck et al., 2013).”
From Intracrine androgen biosynthesis, metabolism and action revisited (2018) · cites this paper as Pretorius et al., 2016
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new mathematical model for relative quantification in real-time RT-PCR
Pfaffl, M. W. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.9.e45 · Cited by 34,610
Primer-BLAST: A tool to design target-specific primers for polymerase chain reaction
Ye, J., Coulouris, G., Zaretskaya, I., Cutcutache, I., Rozen, S., & Madden, T. L. (2012) · BMC Bioinformatics · doi:10.1186/1471-2105-13-134 · Cited by 6,111 · cited 1×
“Reference genes: PBGD [28]: 5’-CATGTCTGGTAACGGCAATG-3’ (forward) and 5’GTACG AGGCTTTCAATGTTG-3’ (reverse), ALAS [29]: 5’-TTCCACAGGAGCCAGCATAC-3’ (forward) and 5’-GGACCTTGGCCTTAGCAGTT-3’ (reverse).”
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586 · cited 1×
“Recent clinical trials demonstrating beneficial clinical outcomes after treatment with the AR antagonist enzalutamide [7] and the CYP17A1 inhibitor abiraterone [8–10] have highlighted the continued androgen dependency of CRPC.”
BackgroundAbiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
LNCaP model of human prostatic carcinoma.
Horoszewicz, J. S., Leong, S. S., Kawinski, E., Karr, J. P., Rosenthal, H. E., Chu, T. M., MIRAND, E. A., & Murphy, G. P. (1983) · PubMed · Cited by 1,789
Fizazi, K., Scher, H. I., Molina, A., Logothetis, C. J., Chi, K. N., Jones, R. J., Staffurth, J. N., North, S., Vogelzang, N. J., Saad, F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70379-0 · Cited by 1,384
Veldscholte, J., Ris-Stalpers, C., Kuiper, G. G. J. M., Jenster, G., Berrevoets, C., Claassen, E., van Rooij, H. C. J., Trapman, J., Brinkmann, A. O., & Mulder, E. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(05)80067-1 · Cited by 950 · cited 1×
“LNCaP cells express a mutated AR (T877A) [32], while VCaP cells express the wild type AR.”
BackgroundAttard, G., Reid, A. H. M., A'Hern, R., Parker, C., Oommen, N. B., Folkerd, E., Messiou, C., Molife, L. R., Maier, G., Thompson, E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0642 · Cited by 605
Holzbeierlein, J., Lal, P., LaTulippe, E., Smith, A., Satagopan, J., Zhang, L., Ryan, C., Smith, S., Scher, H., Scardino, P., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63112-4 · Cited by 577 · cited 1×
“The AR and AR-regulated genes are expressed in most clinical cases of CRPC demonstrating that the AR axis is reactivated and drives tumour growth [4,5].”
BackgroundStandardization of real-time PCR gene expression data from independent biological replicates
Willems, E., Leyns, L., & Vandesompele, J. (2008) · Analytical Biochemistry · doi:10.1016/j.ab.2008.04.036 · Cited by 490 · cited 1×
“Data from individual experiments was all normalized using log transformation and mean-centering prior to analysis [49].”
Method
Cited by
Congenital adrenal hyperplasia
El-Maouche, D., Arlt, W., & Merke, D. P. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31431-9 · Cited by 669
Witchel, S. F., Oberfield, S. E., & Peña, A. S. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00078 · Cited by 653
“Testosterone, DHT, 11-ketotestosterone, and 11-ketodihydrotestosterone bind to the human ARand promote AR-regulated gene expression [33].”
BackgroundSchiffer, L., Barnard, L., Baranowski, E. S., Gilligan, L. C., Taylor, A. E., Arlt, W., Shackleton, C. H. L., & Storbeck, K.-H. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.105439 · Cited by 450
Self-citation11-Oxygenated C19 steroids are the predominant androgens in polycystic ovary syndrome
O’Reilly, M. W., Kempegowda, P., Jenkinson, C., Taylor, A. E., Quanson, J. L., Storbeck, K.-H., & Arlt, W. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3285 · Cited by 267
Self-citationSteroidogenesis: Unanswered Questions
Miller, W. L. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2017.09.002 · Cited by 226
11-Oxygenated androgens in health and disease
Turcu, A. F., Rege, J., Auchus, R. J., & Rainey, W. E. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0336-x · Cited by 217
Intracrine androgen biosynthesis, metabolism and action revisited
Schiffer, L., Arlt, W., & Storbeck, K.-H. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.08.016 · Cited by 217
“Enzymes with 5a-reductase activity can reduce the D4-double bond which, in the presence of the 3-keto and 17b-hydroxyl, leads to maximum androgen potential as is observed for DHT and 11KDHT (Pretorius et al., 2016).”
InfluentialSelf-citationNormal and Premature Adrenarche
Rosenfield, R. L. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab009 · Cited by 188
“For one, not all bioassay systems assess bioactivity at physiologic serum levels, and assessment of endocrine potency at concentrations substantially above this (eg, 100-300 nM) yields potency overestimates (Table 2) (61,64,65).”
BackgroundInfluentialMECHANISMS IN ENDOCRINOLOGY: The sexually dimorphic role of androgens in human metabolic disease
Schiffer, L., Kempegowda, P., Arlt, W., & O’Reilly, M. W. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0124 · Cited by 151
Rege, J., Turcu, A., Kasa-Vubu, J. Z., Lerario, A. M., Auchus, G. C., Auchus, R. J., Smith, J. M., White, P. C., & Rainey, W. E. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00736 · Cited by 154
The Roles of Androgens in Humans: Biology, Metabolic Regulation and Health
Alemany, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911952 · Cited by 133
A new dawn for androgens: novel lessons from 11-oxygenated C19 steroids
Pretorius, E., Arlt, W., & Storbeck, K.-H. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.08.014 · Cited by 142
“The products of the 11OHA4 pathway, 11KT and 11KDHT, have recently been confirmed to be potent AR agonists comparable to T and DHT, respectively (Table 2) (Pretorius et al., 2016).”
InfluentialSelf-citationAndrogens During the Reproductive Years: What Is Normal for Women?
Skiba, M. A., Bell, R. J., Islam, R. M., Handelsman, D. J., Desai, R., & Davis, S. R. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-01357 · Cited by 118
Polycystic Ovary Syndrome: Pathophysiology and Therapeutic Opportunities
Dong, J., & Rees, D. A. (2023) · BMJ Medicine · doi:10.1136/bmjmed-2023-000548 · Cited by 123
Management challenges and therapeutic advances in congenital adrenal hyperplasia
Mallappa, A., & Merke, D. P. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00655-w · Cited by 113
11-oxygenated C19 steroids Do not decline with age in women
Nanba, A. T., Rege, J., Ren, J., Auchus, R. J., Rainey, W. E., & Turcu, A. F. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02527 · Cited by 113
Microbial Hydroxysteroid Dehydrogenases: From Alpha to Omega
Doden, H. L., & Ridlon, J. M. (2021) · Microorganisms · doi:10.3390/microorganisms9030469 · Cited by 118
“(2013) reported that 11β-OHAD leads to the formation of 11-ketotestosterone (11KT) [168], a potent 11-oxygenated C19 androgen involved in castration-resistant prostate cancer [169,170] and polycystic ovary syndrome [170,171].”
BackgroundImplicating androgen excess in propagating metabolic disease in polycystic ovary syndrome
Kempegowda, P., Melson, E., Manolopoulos, K. N., Arlt, W., & O’Reilly, M. W. (2020) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018820934319 · Cited by 70
Clinical significance of 11-oxygenated androgens
Turcu, A. F., & Auchus, R. J. (2017) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000334 · Cited by 80
Monogenic disorders of adrenal steroidogenesis
Baranowski, E. S., Arlt, W., & Idkowiak, J. (2018) · Hormone Research in Paediatrics · doi:10.1159/000488034 · Cited by 79
Sex differences in 11-oxygenated androgen patterns across adulthood
Davio, A., Woolcock, H., Nanba, A. T., Rege, J., O’Day, P., Ren, J., Zhao, L., Ebina, H., Auchus, R., Rainey, W. E., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa343 · Cited by 76
Jones, C. M., Mallappa, A., Reisch, N., Nikolaou, N., Krone, N., Hughes, B. A., O’Neil, D. M., Whitaker, M. J., Tomlinson, J. W., Storbeck, K.-H., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2855 · Cited by 74
Self-citationQuanson, J. L., Stander, M. A., Pretorius, E., Jenkinson, C., Taylor, A. E., & Storbeck, K.-H. (2016) · Journal of Chromatography B · doi:10.1016/j.jchromb.2016.07.024 · Cited by 74
Self-citationBarnard, M., Quanson, J. L., Mostaghel, E., Pretorius, E., Snoep, J. L., & Storbeck, K.-H. (2018) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2018.06.013 · Cited by 72
Self-citationCirculating 11-oxygenated androgens across species
Rege, J., Garber, S., Conley, A. J., Elsey, R. M., Turcu, A. F., Auchus, R. J., & Rainey, W. E. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.04.005 · Cited by 67
“Of these, 11KT is a potent androgen, with bioactivity comparable to that of T [15, 19, 20, 24].”
BackgroundAbiraterone acetate treatment lowers 11-oxygenated androgens
Wright, C., O’Day, P., Alyamani, M., Sharifi, N., & Auchus, R. J. (2020) · European Journal of Endocrinology · doi:10.1530/eje-19-0905 · Cited by 68
“Although 11oxygenated androgens were previously neglected in CRPC, prostate cancer cell lines contain enzymes to convert 11OHA4 to active androgens (28-30), and 11-oxygenated androgens promote growth of these cells (20).”
BackgroundThe role of adrenal derived androgens in castration resistant prostate cancer
Barnard, M., Mostaghel, E. A., Auchus, R. J., & Storbeck, K. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.105506 · Cited by 70
Self-citationLy, L. K., Rowles, J. L., Paul, H. M., Alves, J. M. P., Yemm, C., Wolf, P. M., Devendran, S., Hudson, M. E., Morris, D. J., Erdman, J. W., et al. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.105567 · Cited by 71
Paulukinas, R. D., Mesaros, C. A., & Penning, T. M. (2022) · Endocrinology · doi:10.1210/endocr/bqac068 · Cited by 63
The clinical and biochemical significance of 11-oxygenated androgens in human health and disease
Storbeck, K.-H., & O’Reilly, M. W. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad047 · Cited by 63
Self-citation11-oxygenated C19 steroids as circulating androgens in women with polycystic ovary syndrome
Yoshida, T., Matsuzaki, T., Miyado, M., Saito, K., Iwasa, T., Matsubara, Y., Ogata, T., Irahara, M., & Fukami, M. (2018) · Endocrine Journal · doi:10.1507/endocrj.ej18-0212 · Cited by 59
SULFATION PATHWAYS: Insights into steroid sulfation and desulfation pathways
Foster, P., & Mueller, J. W. (2018) · Journal of Molecular Endocrinology · doi:10.1530/jme-18-0086 · Cited by 67
Nonclassic Congenital Adrenal Hyperplasia
Jha, S., & Turcu, A. F. (2021) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2020.10.008 · Cited by 65
The Rise, Fall, and Resurrection of 11-Oxygenated Androgens in Human Physiology and Disease
Turcu, A. F., Nanba, A. T., & Auchus, R. J. (2018) · Hormone Research in Paediatrics · doi:10.1159/000486036 · Cited by 52
Jayasena, C. N., Alkaabi, F., Liebers, C. S., Handley, T. J., Franks, S., & Dhillo, W. S. (2019) · Clinical Endocrinology · doi:10.1111/cen.13906 · Cited by 57
Gut feelings about bacterial steroid-17,20-desmolase
Ly, L. K., Doden, H. L., & Ridlon, J. M. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111174 · Cited by 47
Circulating steroid hormone variations throughout different stages of prostate cancer
Snaterse, G., Visser, J. A., Arlt, W., & Hofland, J. (2017) · Endocrine Related Cancer · doi:10.1530/erc-17-0155 · Cited by 50
An expanded metabolic pathway for androgen production by commensal bacteria
Wang, T., Ahmad, S., Cruz-Lebrón, A., Ernst, S. E., Caicedo, K. Y. O., Jeong, Y., Binion, B., Mbuvi, P., Dutta, D., Fernández-Materán, F. V., et al. (2025) · Nature Microbiology · doi:10.1038/s41564-025-01979-9 · Cited by 49
“Another study reported that faecal microbiota transplant from donors with metastatic castration-resistant prostate cancer (mCRPC) promotes castration-resistant tumour growth in mice 5 , which is related to the microbial metabolism of host steroids to androgen precursors such as dehydroepiandrosterone (DHEA) and androg…”
InfluentialDoden, H. L., Pollet, R. M., Mythen, S. M., Wawrzak, Z., Devendran, S., Cann, I., Koropatkin, N. M., & Ridlon, J. M. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.009390 · Cited by 45
Schiffer, L., Kempegowda, P., Sitch, A. J., Adaway, J. E., Shaheen, F., Ebbehoj, A., Singh, S., McTaggart, M. P., O’Reilly, M. W., Prete, A., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvac017 · Cited by 42
Androgens in postmenopausal women: a review
Shifren, J. L., & Davis, S. R. (2017) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000903 · Cited by 48
Gent, R., du Toit, T., Bloem, L. M., & Swart, A. C. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.02.013 · Cited by 41
Steroid metabolism in breast cancer: Where are we and what are we missing?
Africander, D., & Storbeck, K. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.05.016 · Cited by 44
Self-citationAndrogen receptor mutations modulate activation by 11-oxygenated androgens and glucocorticoids
Snaterse, G., Mies, R., van Weerden, W. M., French, P. J., Jonker, J. W., Houtsmuller, A. B., van Royen, M. E., Visser, J. A., & Hofland, J. (2022) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-022-00491-z · Cited by 41
Jha, S., Turcu, A. F., Sinaii, N., Brookner, B., Auchus, R. J., & Merke, D. P. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa192 · Cited by 39
Conceptualizing the Vertebrate Sterolbiome
Ridlon, J. M. (2020) · Applied and Environmental Microbiology · doi:10.1128/aem.00641-20 · Cited by 37
“The conversion of allodihydrocortisone to allodihydro-11-keto-testosterone through the combination of steroid-17,20-desmolase and bacterial 17 -HSDH generates a potent androgen (140, 141).”
Backgrounddu Toit, T., & Swart, A. C. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.09.026 · Cited by 34
“These C11-oxy steroids are readily reduced by SRD5A, with 11KT and 11KDHT capable of activating the AR to the same degree as DHT, and of inducing androgen dependent gene expression (Bloem et al., 2015; Pretorius et al., 2016; Storbeck et al., 2013).”
Caron, P., Turcotte, V., & Guillemette, C. (2021) · Journal of Chromatography A · doi:10.1016/j.chroma.2021.462228 · Cited by 35
Turcu, A. F., El-Maouche, D., Zhao, L., Nanba, A. T., Gaynor, A., Veeraraghavan, P., Auchus, R. J., & Merke, D. P. (2020) · European Journal of Endocrinology · doi:10.1530/eje-20-0129 · Cited by 33
du Toit, T., & Swart, A. C. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.105497 · Cited by 32
Bui, N.-N., Li, C., Wang, L., Chen, Y., Kao, W.-H., Chou, L., Hsieh, J., Lin, H., & Lai, C. (2023) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2022.12.009 · Cited by 32
Hawley, J. M., Adaway, J., Owen, L. J., & Keevil, B. G. (2020) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2019-0959 · Cited by 31
“In androgen-dependent prostate cancer cells, 11KT can drive cellular proliferation, thus suggesting it contributes to the development and progression of CRPC; hence, its measurement may help assess treatment [5].”
BackgroundInfluentialTosi, F., Villani, M., Garofalo, S., Faccin, G., Bonora, E., Fiers, T., Kaufman, J., & Moghetti, P. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab920 · Cited by 32
Nowotny, H. F., Braun, L., Vogel, F., Bidlingmaier, M., Reincke, M., Tschaidse, L., Auer, M. K., Lottspeich, C., Wudy, S. A., Hartmann, M. F., et al. (2022) · European Journal of Endocrinology · doi:10.1530/eje-22-0320 · Cited by 32
“11-keto-testosterone (11KT) and 11-keto-dihydrotestosterone (11KDHT) have been shown to be active androgens with equal potency at the androgen receptor as testosterone (T) and dihydrotestosterone (DHT), respectively (17).”
BackgroundInfluentialTargeting sex steroid biosynthesis for breast and prostate cancer therapy
POUTANEN, M. H., Thulin, M. H., & Härkönen, P. L. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00609-y · Cited by 32
Barnard, L., du Toit, T., & Swart, A. C. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111189 · Cited by 34
Ostinelli, G., Vijay, J., Vohl, M., Grundberg, E., & Tchernof, A. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111220 · Cited by 32
Idkowiak, J., Elhassan, Y., Mannion, P., Smith, K. A., Webster, R., Saraff, V., Barrett, T. G., Shaw, N. J., Krone, N. P., Dias, R. P., et al. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0854 · Cited by 29
“The adrenal P450 cytochrome 11 β -hydroxylase (CYP11B1) enzyme efficiently converts A4 to 11-hydroxy-androstenedione, which can be further converted to 11-ketotestosterone (11KT), which has been shown to bind and activate the androgen receptor with similar potency to testosterone (24, 28, 29).”
María, M. D., Kroll, K. J., Yu, F., Nouri, M., Silva-Sánchez, C., Pérez, J. G., Amador, D. A. M., Zhang, Y., Walsh, M. T., & Denslow, N. D. (2022) · Aquatic Toxicology · doi:10.1016/j.aquatox.2022.106142 · Cited by 29
Integration of androgen hormones in endometrial cancer biology
Gjorgoska, M., & Rižner, T. L. (2022) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2022.06.001 · Cited by 30
Adrenals Contribute to Growth of Castration-Resistant VCaP Prostate Cancer Xenografts
Huhtaniemi, R., Oksala, R., Knuuttila, M., Mehmood, A., Aho, E., Laajala, T. D., Nicorici, D., Aittokallio, T. A., Laiho, A., Elo, L. L., et al. (2018) · American Journal Of Pathology · doi:10.1016/j.ajpath.2018.07.029 · Cited by 29
Barnard, L., Schiffer, L., Louw du-Toit, R., Tamblyn, J. A., Chen, S., Africander, D., Arlt, W., Foster, P. A., & Storbeck, K.-H. (2021) · Endocrinology · doi:10.1210/endocr/bqaa231 · Cited by 27
Self-citationActivin A and Sertoli Cells: Key to Fetal Testis Steroidogenesis
O’Donnell, L., Whiley, P. A. F., & Loveland, K. L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.898876 · Cited by 26
“They are likely to be synthesized in human peripheral tissues from the abundant adrenal steroid 11b-hydroxyandrostenedione (11OHA4) (Figure 1B) (46, 54).”
BackgroundBarnard, L., Nikolaou, N., Louw, C., Schiffer, L., Gibson, H., Gilligan, L. C., Gangitano, E., Snoep, J., Arlt, W., Tomlinson, J. W., et al. (2020) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2020.105724 · Cited by 25
“Moreover, 11KT may be resistant to peripheral inactivation by glucuronidation [8,55].”
BackgroundSelf-citationPeripheral blood mononuclear cells preferentially activate 11-oxygenated androgens
Schiffer, L., Bossey, A., Kempegowda, P., TAYLOR, A. E. R., Akerman, İ., Scheel‐Toellner, D., Storbeck, K., & Arlt, W. (2021) · European Journal of Endocrinology · doi:10.1530/eje-20-1077 · Cited by 26
“11KT activates the androgen receptor with potency and efficacy similar to T (11-13) and is the predominant circulating androgen in androgen excess conditions including congenital adrenal hyperplasia, polycystic ovary syndrome and premature adrenarche (12, 14, 15).”
BackgroundSelf-citationBioactivity of 11 keto and hydroxy androgens in yeast and mammalian host cells
Handelsman, D. J., Cooper, E. R., & Heather, A. K. (2022) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2021.106049 · Cited by 23
Schiffer, L., Adaway, J., Arlt, W., & Keevil, B. G. (2019) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563219847498 · Cited by 22
“11OHA4 can be further converted to 11-ketotestosterone (11KT), which activates the androgen receptor with the same potency and efficacy as testosterone.(10,11) In both common (PCOS) and rare (CAH) androgen excess conditions, 11-oxygenated androgens make the major contribution to the circulating androgen pool.”
Exploring the Predictive Role of 11‐Oxyandrogens in Diagnosing Polycystic Ovary Syndrome
Mody, A., Lodish, M. B., Auchus, R. J., Turcu, A. F., Jiang, F., & Huddleston, H. G. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70022 · Cited by 21
“…interest is 11-ketotestosterone, which has similar androgenic activity to that of testosterone in in vitro studies [8, 11] and can be converted peripherally via 5-alpha reductase to 11-ketodihydrotestosterone, a potent androgen with similar activity to dihydrotestosterone (Figure S1) [12, 13].”
Endo, S., Morikawa, Y., Kudo, Y., Suenami, K., Matsunaga, T., Ikari, A., & Hara, A. (2020) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2020.105586 · Cited by 21
Yang, J., Peng, G., Shu, F., Dong, D., Zheng, X., Zhu, C., Li, X. O., Ma, J., Pan, C., Yang, F., et al. (2021) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2021.105916 · Cited by 23
Mao, Y., Yang, G., Li, Y., Liang, G., Xu, W., & Hu, M. (2022) · Cancers · doi:10.3390/cancers14153744 · Cited by 23
“Nishiyama et al. further conducted a Gleason score analysis of the CRPC patients in which they found tha the low levels of DHT in t ese patients were sufficient to promote AR receptor activation and tumor progression [19,26,27].”
BackgroundInfluentialTurcu, A. F., Mallappa, A., Nella, A. A., Chen, X., Zhao, L., Nanba, A. T., Byrd, J. B., Auchus, R. J., & Merke, D. P. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.751191 · Cited by 20
Androgenic potential of human fetal adrenals at the end of the first trimester
Savchuk, I., Morvan, M. L., Antignac, J. P., Gemzell-Danielsson, K., Le Bizec, B., Söder, O., & Svechnikov, K. (2017) · Endocrine Connections · doi:10.1530/ec-17-0085 · Cited by 20
Circadian Rhythms of 11-Oxygenated C19 Steroids and 5-Steroid Sulfates in Healthy Men
Turcu, A. F., Zhao, L., Chen, X., Yang, R., Rege, J., Rainey, W. E., Veldhuis, J. D., & Auchus, R. J. (2021) · European Journal of Endocrinology · doi:10.1530/eje-21-0348 · Cited by 19
Steroidogenesis in castration-resistant prostate cancer
Shiota, M., Endo, S., Blas, L., Fujimoto, N., & Eto, M. (2022) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2022.10.018 · Cited by 22
11-Ketotestosterone is the predominant active androgen in prostate cancer patients after castration
Snaterse, G., van Dessel, L. F., van Riet, J., TAYLOR, A. E. R., van der Vlugt‐Daane, M., Hamberg, P., de Wit, R., Visser, J. A., Arlt, W., Lolkema, M. P., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.148507 · Cited by 23
“We hypothesized that due to the adrenal origin of its precursors, 11KT may persist after castration and may therefore exceed the residual concentrations of T and DHT in patients with CRPC. Similarly, the 11-oxygenated precursor steroids 11 β -hydroxyandrostenedione (11OHA4), 11-ketoandrostenedione (11KA4), and 11 β -h…”
InfluentialAndrogens and Non-Genomic vascular responses in hypertension
Perusquía, M. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115200 · Cited by 18
Wu, Y., Tang, L., Azabdaftari, G., POP, E. A., & Smith, G. J. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.02.018 · Cited by 17
Lempiäinen, J. K., Manjur, A. B. M. K., Malinen, M., Ketola, K., Niskanen, E. A., & Palvimo, J. J. (2020) · Oncogene · doi:10.1038/s41388-020-1153-3 · Cited by 17
Schiffer, L., Oestlund, I., Snoep, J. L., Gilligan, L. C., TAYLOR, A. E. R., Sinclair, A. J., Singhal, R., Freeman, A., Ajjan, R., Tiganescu, A., et al. (2024) · The FASEB Journal · doi:10.1096/fj.202302131r · Cited by 18
“This increase in androgen load is significant given that 11KT has shown functional activity 344 comparable to testosterone (5, 53, 58) and increased circulating androgens have been linked to a 345”
BackgroundSelf-citationSchiffer, L., Arlt, W., & Storbeck, K. (2024) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2024.106516 · Cited by 16
Self-citation11-Keto-testosterone and Other Androgens of Adrenal Origin
Stárka, L., Dušková, M., & Vítků, J. (2020) · Physiological Research · doi:10.33549/physiolres.934516 · Cited by 16
Dahmani, C., Caron, P., Simonyan, D., Lacombe, L., Aprikian, A. G., Saad, F., Carmel, M., Chevalier, S., Lévesque, É., & Guillemette, C. (2022) · The Journal of Urology · doi:10.1097/ju.0000000000003049 · Cited by 14
Park, C. G., Adnan, K. M., Cho, H., Ryu, C. S., Yoon, J., & Kim, Y. J. (2024) · Toxicology in Vitro · doi:10.1016/j.tiv.2024.105838 · Cited by 15
Quantification of androgens and their precursors in full-term human placenta
Yoshida, T., Matsumoto, K., Miyado, M., Miyashiro, Y., Sago, H., Horikawa, R., & Fukami, M. (2021) · European Journal of Endocrinology · doi:10.1530/eje-21-0312 · Cited by 13
Mutation of HSD3B2 Gene and Fate of Dehydroepiandrosterone
Baquedano, M. S., Guercio, G., Costanzo, M., Marino, R. M., Rivarola, M. A., & Belgorosky, A. (2018) · Vitamins and hormones · doi:10.1016/bs.vh.2018.05.002 · Cited by 14
Kudo, Y., Endo, S., Tanio, M., Saka, T., Himura, R., Abe, N., Takeda, M., Yamaguchi, E., Yoshino, Y., Arai, Y., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214356 · Cited by 14
“[17] reported that 11KDHT and 11KT exhibit androgenic activity comparable to DHT and T in LNCaP and VCaP cell lines.”
BackgroundRittig, N. F., Arlien-Søborg, M. C., Svart, M. V., Thomsen, H. H., Kirkegaard, K., Greve, V. H., Nielsen, M. M., Stochholm, K., Ørnstrup, M. J., & Gravholt, C. H. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf106 · Cited by 12
Rohayem, J., Zitzmann, M., Laurentino, S., Kliesch, S., Nieschlag, E., Holterhus, P., & Kulle, A. E. (2020) · Clinical Endocrinology · doi:10.1111/cen.14324 · Cited by 12
Skiba, M. A., Bell, R. J., Islam, R. M., Karim, M. N., & Davis, S. R. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa063 · Cited by 12
Dahmani, C., Caron, P., Simonyan, D., Turcotte, V., Grégoire, J., Plante, M., & Guillemette, C. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1156680 · Cited by 11
“The dotted arrows for the conversion of 11KAST to 11OHAST and 11K5adione to 11OH5adione represent biotransformation inconsistently reported in the literature (33, 34, 36, 39).”
BackgroundApplying mass spectrometric methods to study androgen biosynthesis and metabolism in prostate cancer
Knuuttila, M., Hämäläinen, E. K., & POUTANEN, M. H. (2019) · Journal of Molecular Endocrinology · doi:10.1530/jme-18-0150 · Cited by 11
Davis, S. R., Turcu, A. F., Robinson, P. J., & Bell, R. J. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2018-00412 · Cited by 10
Canonical and Noncanonical Androgen Metabolism and Activity
Storbeck, K., & Mostaghel, E. A. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-32656-2_11 · Cited by 12
Self-citationDetermination of Intraprostatic and Intratesticular Androgens
Šimková, M., Heráček, J., Drašar, P., & Hampl, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22010466 · Cited by 10
“Using cancer cell lines LNCaP and VCaP, it was proven that they bind to the androgen receptor with affinities close to that of testosterone and dihydrotestosterone and induced both the expression of representative androgen receptor-regulated genes as well as cellular proliferation in the androgen-dependent prostate [1…”
BackgroundA commentary on the origins of 11-ketotestosterone
Storbeck, K. (2022) · European Journal of Endocrinology · doi:10.1530/eje-22-0820 · Cited by 12
Self-citationGut bacteria convert cortisol into a distinct host signalling moleculePreprint
Freiberg, M., Wang, T., Rosa, R. S. D. L., Oßwald, A., Melo, M. C. R., Stouffer, D. G., Buobu, P. S., Welsh, C., Yang, L., Abdel-Hamid, A. M., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.12.149468 · Cited by 12
“Recently, these novel androgens have been shown to be relevant to human physiology and pathology, including castration-resistant prostate cancer (29, 31), polycystic ovary syndrome (30, 32), and potentially hypertension (22, 33–36).”
BackgroundHarding, B. N., Espinosa, A., Castaño‐Vinyals, G., Pozo, Ó. J., Skene, D. J., Bustamante, M., Mata, M., Aguilar, R., Dobaño, C., Wucher, V., et al. (2024) · Journal of Pineal Research · doi:10.1111/jpi.70017 · Cited by 8
Hou, Z., Yang, T., Mei, Z., Zhang, S., Gao, Y., Chen, X., Tan, Q., Zhu, X., Xu, C., Lian, J., et al. (2021) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2021.105859 · Cited by 8
11-Oxyandrogens from the viewpoint of pediatric endocrinology
Fukami, M. (2022) · Clinical Pediatric Endocrinology · doi:10.1297/cpe.2022-0029 · Cited by 7
“Reportedly, the binding activities of 11-KT and 11-KDHT to AR are comparable to those of T and DHT, respectively (8, 9).”
Background
Metadata
- Authors
- Pretorius, E., Africander, D. J., Vlok, M., Perkins, M. S., Quanson, J., & Storbeck, K.-H.
- Affiliations
- Stellenbosch University (ZA)
- Corresponding author
- Pretorius, Elzette
- Africander, Donita J.
- Vlok, Maré
- Perkins, Meghan S.
- Quanson, Jonathan
- Storbeck, Karl-Heinz
- ORCID
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-07-21
- Volume
- 11
- Issue
- 7
- Pages
- e0159867
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4956299
- OpenAlex
- W2501835417
- Cited by
- 148
- References
- 55
- Citations by year
- 2026: 14 · 2025: 10 · 2024: 11 · 2023: 13 · 2022: 18 · 2021: 20 · 2020: 20 · 2019: 15 · 2018: 12 · 2017: 11 · 2016: 4
- FWCI
- 12.52
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- SUNScholar (Stellenbosch University) (submittedVersion)
- Funders
- National Research Foundation of South Africa (TTK1206061092)
- Cancer Association of South Africa
- Universiteit Stellenbosch
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- 11-ketotestosterone, castration-resistant prostate cancer, androgen receptor, 11β-hydroxyandrostenedione, androgen metabolism, androgen-dependent gene expression, prostate cancer cell proliferation, LNCaP cells, VCaP cells
- MeSH terms
- Androgens, Animals, Humans, Male, Protein Binding, Receptors, Androgen, Testosterone, Response Elements, Cell Line, Tumor, Cell Proliferation, Biosynthetic Pathways, Prostatic Neoplasms, Castration-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.